The FDA has issued a positive review of Gilead Sciences' hepatitis C drug sofosbuvir, saying that it is safe and effective in combination with other treatments. The review precedes an outside panel meeting on whether to recommend the drug's approval. The drug could become the first approved all-oral treatment for genotypes 2 and 3 of hepatitis C.

Full Story:

Related Summaries